Loading...
Market
PTC Therapeutics' Investment Strategy in Duchenne Muscular Dystrophy Research Over the Next Year
2
Resolution / Starting Odds
Increase investment • 33%
Maintain current investment level • 34%
Decrease investment • 33%
Press releases from PTC Therapeutics or financial disclosures
Story
European Commission's Unprecedented Move Boosts PTC Therapeutics' Stock by 17%
May 20, 2024, 09:22 PM
The European Commission has decided not to adopt the Committee for Medicinal Products for Human Use's (CHMP) negative opinion on the annual renewal of the conditional marketing authorization of PTC Therapeutics' drug Translarna. The decision, described as 'unprecedented' and 'highly unusual,' has sent the matter back to the CHMP for re-evaluation. This move comes despite Translarna's failure in its confirmatory study for Duchenne muscular dystrophy. Following the announcement, PTC Therapeutics' stock ($PTCT) surged by 17%, reaching a nine-month high.
View original story
Similar markets
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
Increased investment in existing Alzheimer's drugs • 33%
Development of new APOE4-specific treatments • 33%
No significant change in investment • 33%
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
Yes • 50%
No • 50%
Significant stock value increase • 33%
Moderate stock value increase • 33%
No significant change • 34%
Success • 33%
Partial Success • 33%
Failure • 33%
Pfizer • 25%
Sarepta Therapeutics • 25%
Solid Biosciences • 25%
Other • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%
Seek further regulatory approvals • 33%
Begin commercial production • 33%
Partner with another company for distribution • 34%